tiprankstipranks
Rebus Holdings (RBSH)
OTHER OTC:RBSH
US Market

Rebus Holdings (RBSH) Stock Price & Analysis

43 Followers

RBSH Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range<$0.01 - $0.02
Previous Close$0.01
Volume28.00
Average Volume (3M)N/A
Market Cap
$3.21K
Enterprise Value-$1.79K
Total Cash (Recent Filing)$5.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)1.6
Beta0.16
Apr 01, 2021
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding32,132,907
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-0.04
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.07
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

19.05%0.00%<0.01%80.95%
19.05%
Insiders
0.00%
Mutual Funds
<0.01% Other Institutional Investors
80.95% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

RBSH FAQ

What was Rebus Holdings’s price range in the past 12 months?
Rebus Holdings lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
    What is Rebus Holdings’s market cap?
    Currently, no data Available
    When is Rebus Holdings’s upcoming earnings report date?
    Rebus Holdings’s upcoming earnings report date is Apr 01, 2021 which is 1127 days ago.
      How were Rebus Holdings’s earnings last quarter?
      Rebus Holdings released its earnings results on Nov 24, 2020. The company reported -$0.019 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.019.
        Is Rebus Holdings overvalued?
        According to Wall Street analysts Rebus Holdings’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Rebus Holdings pay dividends?
          Rebus Holdings does not currently pay dividends.
          What is Rebus Holdings’s EPS estimate?
          Rebus Holdings’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Rebus Holdings have?
          Rebus Holdings has 32,132,908 shares outstanding.
            What happened to Rebus Holdings’s price movement after its last earnings report?
            Rebus Holdings reported an EPS of -$0.019 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of Rebus Holdings?
              Currently, no hedge funds are holding shares in RBSH
              ---

              Rebus Holdings Stock Smart Score

              N/A
              Not Ranked
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Company Description

              Rebus Holdings

              Inspyr Therapeutics, Inc. is a pharmaceutical company, which focuses on the development of prodrug cancer therapeutics for the treatment of solid tumors. The company's prodrug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. Its technology platform combines a powerful cytotoxin with a patented prodrug delivery system that targets the release of the drug within the tumor. Inspyr Therapeutics was founded by Craig A. Dionne, John T. Issacs and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Home Solutions Health
              GeneThera
              US BioTec
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis